Eli Lilly Stock - Analyst consensus stays bullish on weight-loss boom
20.06.2026 - 20:25:09 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 20:23 UTC. Details in the imprint.
Eli Lilly and Company (US5324571083) sits near the top tier of global healthcare by market value. Analyst data compiled over the past days still show a dominant Buy stance on the stock as investors center on its obesity and diabetes pipeline.
All news and analysis on Eli Lilly stock
From analyst ratings to obesity-drug demand, our topic page collects current headlines, data and background on Eli Lilly shares.
What the analyst data show
Recent consensus snapshots point to a clear majority of Buy recommendations on Eli Lilly shares, with one data provider counting 24 Buy and 5 Hold ratings out of 31 analysts covering the stock. The average 12-month price target clusters around $1,215 per share.
That implies a low-double-digit percentage upside from the current level, underlining that most brokers still see structural growth ahead despite a rich valuation. Rating language in recent months has largely focused on obesity and diabetes revenue potential as the core driver.
How the valuation stacks up
On recent quotes around $1,098 per share, Eli Lilly commands a market capitalization close to $1.0 trillion, placing it among the world’s most valuable listed healthcare groups. The stock trades on a trailing price/earnings multiple just below 39.
That premium reflects expectations for sustained high growth from its metabolic and neuroscience portfolios rather than the broader pharmaceuticals sector trend. Against this backdrop, investors are watching closely whether earnings growth can keep pace with the valuation over the coming years.
The business behind the stock
Eli Lilly generates most of its revenue from human pharmaceuticals, with flagship products in diabetes, obesity, oncology, immunology and neuroscience. Its current growth story is anchored in incretin-based drugs for weight management and type 2 diabetes, alongside an advancing pipeline of next-generation therapies.
Where the stock trades today
The shares of Eli Lilly and Company (US5324571083) last closed on the New York Stock Exchange at $1,098.78 on 06/18/2026, 16:00 ET.
Key facts on Eli Lilly stock
- Company: Eli Lilly and Company Inc.
- ISIN: US5324571083
- WKN: 858560
- Ticker: LLY
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 1,098.78 USD
- Market cap: 991,600,000,000 USD (as of 06/18/2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
